GLOBAL BLOOD THERAPEUTICS Stock News

Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Regeneron ( REGN – Research Report ) today and set a price target of $409.00 . The company’s shares closed last Wednesday at $51

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Regeneron (REGN), Amgen (AMGN) and Eli Lilly & Co

Nomura analyst Christopher Marai maintained a Sell rating on Alnylam Pharma (ALNY) today and set a price target of $74.00. The company's shares closed

Nomura analyst Christopher Marai maintained a Sell rating on Alnylam Pharma (ALNY – Research Report) today and set a price

Nuveen Asset Management LLC lowered its holdings in shares of Global Blood Therapeutics Inc (NASDAQ:GBT) by 47.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund own

Nigeria’s leading telecoms service provider, 9mobile, has thrown its weight behind Mobihealth international, an award-winning telemedicine provider, to...

BidaskClub upgraded shares of Global Blood Therapeutics (NASDAQ:GBT) from a sell rating to a hold rating in a report published on Thursday, BidAskClub reports. GBT has been the topic of several other

In a report issued on April 6, Christopher Marai from Nomura maintained a Buy rating on Incyte (INCY), with a price target of $116.00. The company's

In a report issued on April 6, Christopher Marai from Nomura maintained a Buy rating on Incyte ( INCY – Research Report ), with a price target of $116.00 . The company’s shares closed last Tuesday

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biogen (BIIB), Alnylam Pharma (ALNY) and Agios Pharma

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioNano Genomics (BNGO) and PTC Therapeutics (PTCT) with

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioNano Genomics